METOPROLOL SUCCINATE tablet, extended release

Kraj: Stany Zjednoczone

Język: angielski

Źródło: NLM (National Library of Medicine)

Składnik aktywny:

METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23)

Dostępny od:

Bryant Ranch Prepack

Droga podania:

ORAL

Typ recepty:

PRESCRIPTION DRUG

Wskazania:

Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic

Podsumowanie produktu:

NDC: 63629-8100-1: 30 Tablets in a BOTTLE

Status autoryzacji:

Abbreviated New Drug Application

Charakterystyka produktu

METOPROLOL SUCCINATE- METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE
BRYANT RANCH PREPACK
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
METOPROLOL SUCCINATE
EXTENDED-RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS
METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS FOR ORAL USE.
INITIAL U.S. APPROVAL:1992
WARNING: ISCHEMIC HEART DISEASE
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
FOLLOWING ABRUPT CESSATION OF THERAPY WITH BETA-BLOCKING AGENTS,
EXACERBATIONS OF
ANGINA PECTORIS AND MYOCARDIAL INFARCTION HAVE OCCURRED. WARN PATIENTS
AGAINST
INTERRUPTION OR DISCONTINUATION OF THERAPY WITHOUT THE PHYSICIAN'S
ADVICE. (5.1)
INDICATIONS AND USAGE
Metoprolol succinate, is a beta -selective adrenoceptor blocking
agent.
Metoprolol succinate extended-release tablets, USP are indicated for
the treatment of:
Hypertension, to lower blood pressure. Lowering blood pressure reduces
the risk of fatal and non-fatal
cardiovascular events, primarily strokes and myocardial infarctions.
(1.1)
Angina Pectoris. (1.2)
Heart Failure - for the treatment of stable, symptomatic (NYHA Class
II or III) heart failure of ischemic,
hypertensive, or cardiomyopathic origin. (1.3)
DOSAGE AND ADMINISTRATION
Administer once daily. Dosing of metoprolol succinate extended-release
tablets, USP should be
individualized. (2)
Heart Failure: Recommended starting dose is 12.5 mg or 25 mg doubled
every two weeks to the
highest dose tolerated or up to 200 mg. (2.3)
Hypertension: Usual initial dosage is 25 to 100 mg once daily. The
dosage may be increased at weekly
(or longer) intervals until optimum blood pressure reduction is
achieved. Dosages above 400 mg per
day have not been studied. (2.1)
Angina Pectoris: Usual initial dosage is 100 mg once daily. Gradually
increase the dosage at weekly
intervals until optimum clinical response has been obtained or there
is an unacceptable bradycardia.
Dosages above 400 m